AstraZeneca price target raised to $85 from $80 at Argus

Argus raised the firm’s price target on AstraZeneca to $85 from $80 and keeps a Buy rating on the shares. The firm cites the company having received a range of new product approvals in recent months, including treatments targeting rare blood disorders, solid tumors, respiratory syncytial virus, and an autoimmune disease that affects the central nervous system. AstraZeneca has also made use of acquisitions to bolster its growth, having recently completed an equity investment in Cellectis and an acquisition of Gracell Biotechnologies, as well as announcing plans to acquire Fusion Pharmaceuticals and Amolyt Pharma, Argus added.